GT Biopharma
GTBP
53 hedge funds and large institutions have $16.7M invested in GT Biopharma in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 11 closing their positions.
283% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 6
40% more call options, than puts
Call options by funds: $334K | Put options by funds: $239K
0.08% more ownership
Funds ownership: 0.52% → 0.6% (+0.08%)
0% more funds holding
Funds holding: 53 → 53 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
48% less capital invested
Capital invested by funds: $32.1M → $16.7M (-$15.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.21M |
| 2 |
Renaissance Technologies
New York
|
+$1.11M |
| 3 |
Morgan Stanley
New York
|
+$950K |
| 4 |
Two Sigma Advisers
New York
|
+$343K |
| 5 |
State Street
Boston,
Massachusetts
|
+$272K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCP
Silverleafe Capital Partners
Germantown,
Tennessee
|
-$708K |
| 2 |
D.E. Shaw & Co
New York
|
-$416K |
| 3 |
Millennium Management
New York
|
-$230K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$227K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$181K |
GTBP Hedge Fund Activity: Q4 2021 in Review
53 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2021, worth a combined $16.7M — down 48% from $32.1M a quarter earlier.
Fund positioning in GTBP was balanced in Q4 2021: 11 funds opened new positions, 11 closed out, 23 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.21M. The largest seller was Silverleafe Capital Partners, exiting entirely with an estimated $708K sold.
- 53 institutional investors held GT Biopharma (GTBP) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $16.7M of GT Biopharma stock for Q4 2021, down 48% quarter-over-quarter.
- 11 funds opened new GT Biopharma positions in Q4 2021 and 11 closed out, a net change of 0 holders.
- The largest GT Biopharma buyer in Q4 2021 was Vanguard Group, an estimated $1.21M added.
- The largest GT Biopharma seller in Q4 2021 was Silverleafe Capital Partners, an estimated $708K sold.
Based on aggregated 13F filings for Q4 2021.